Five local authorities have been rated non-compliant by the Regulator of Social Housing after “serious failings” on issues ...

As Lollapalooza returns to Chicago’s Grant Park this weekend, organizers are once again turning up the volume on ...

There are already different rules regarding liquid allowances across Europe, leading to confusion among travellers.

Airports across the UK are enforcing different 100ml liquid systems, threatening to cause hold-ups in security lanes as the ...

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

The system will play an essential role in Central Finland’s hydrogen production and contribute to the region’s ...

C3.ai, Inc. AI is capitalizing on the booming demand for enterprise AI. However, the company now faces a critical challenge.

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...